Skip to main content

Mitesco Inc

For the period ended Dec 31, 2023. Filed Apr 16, 2024.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Apr 16, 2024

MITIStored price and day change unavailable

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Item 11. Executive Compensation

Summary of Executive Compensation

Three directors were appointed on December 15, 2023, replacing the previous Board of Directors. They have elected to receive no compensation for 2023.

The following summary compensation table sets forth all compensation awarded to, earned by, or paid to the named executive officers paid by us during the periods ended December 31, 2023 and 2022.

Summary Compensation Table

Salary · Salary
earned · earned · Non-Equity · Nonqualified
and · and · Incentive · Deferred · All
Name and · paid · unpaid · Stock · Option · Plan · Compensation · Other
Principal · in cash · in cash · Bonus · Awards · Awards · Compensation · Earnings · Compensation · Total
PositionYear($)($)($)($)($)($)($)($)($)
Mack Leath2023---------
Chief Executive Officer and Chief Financial Officer2022---------
Lawrence Diamond20237,000233,385----634,114(a)874,499
Former Chief Executive Officer2022177,88577,460-----14,384(b)269,729
Thomas Brodmerkel2023-115,385-----95,791(a)211,176
Former Chief Financial Officer202228,84638,792--23,316(c)--6,291(b)97,245
Jenny Lindstrom2023-96,154------96,154
Former Chief Legal Officer2022182,69377,183-----14,394(b)274,260
Shelia Schweitzer2023-109,231------109,231
Former Chief Operating Officer2022---------
Jessica Finnegan20237,000109,827------116,827
VP Human Resources2022121,77765,007------186,784
For "The Good Clinic, LLC" subsidiary
Michael Howe20231,0001,349-----49,895(a)52,244
Former Chief Executive Officer2022134,61533,215-----8,986(b)176,817
Bradley Case20232,00021,077------23,077
Former President2022138,46259,913-----11,659(b)210,033
(a)Consists of an equity incentive for the conversion of notes and accrued compensation into Series F preferred shares
(b)Consists of reimbursement for health insurance and cell phone costs.
(c)Consists of the fair value of 4,000 stock options granted during the period.
(d)Consists of severance pay in the amount of $19,230 and reimbursement for health insurance and cell phone costs in the Amount of $8,130.

Executive Employment, Termination and Change of Control Arrangements

The Company appointed three (3) new Directors on December 15, 2023. They have elected to receive no compensation for 2023.

They have agreed to serve for one (1) year terms and have agreed to a compensation plan that provides for a) $60,000 per year stipend to be paid by the issuance of Series X Preferred Stock, and b) reimbursement of any real and actual cash expenses incurred in the execution of their responsibilities such as travel, office supplies or similar nominal expenses.

The Series X Preferred shares have a face value of $25 per share and pay dividend of 10% in cash or through the issuance of restricted common stock monthly. All dividends to date for previously issued shares have been paid through the issuance of restricted common stock, and it is anticipated that this practice will continue indefinitely.

For 2024, in conjunction with this award each of the Directors will receive a total of 2,400 shares of Series X Preferred stock. Each share has voting rights entitling it to four hundred (400) votes, when compared to common stock which has one (1) vote per share. As such each director will be entitled to 960,000 share votes on any matter requiring a vote.

Starting in July 2023 and continuing until further notice the Company intends to pay the Series X dividends using restricted common stock with a valuation of $.80 per share, a 20% discount to the average price of the stock before it was moved to the OTC Expert Market Quote platform.

The Certificate of Designation for the Series X Preferred stock (as previously filed in Delaware, and recently converted to Nevada with the same terms) can be viewed here: https://www.sec.gov/Archives/edgar/data/802257/000118518520000019/ex_168535.htm

Officer Compensation

Effective December 15, 2023, the officers of the Company shall not receive any compensation, either accrued or paid.

Pension Benefits; Nonqualified Defined Contribution and Other Nonqualified Deferred Compensation Plans

We do not offer pension benefits, non-qualified contribution, or other deferred compensation plans to our executive officers.

Outstanding Equity Awards at December 31, 2023

The following table shows for the fiscal year ended December 31, 2023, certain information regarding outstanding equity awards at fiscal year-end for the Named Executive Officers. None of the newly elected Named Executive Officers have outstanding equity awards at December 31, 2023.

Note: In January 2024 the Board of Directors terminated the stock option plan, and all previously issued options.

The details can be found here: https://www.sec.gov/ix?doc=/Archives/edgar/data/0000802257/000118518524000060/mitesco20240109_8k.htm

Securities · Securities
Underlying · Underlying
Unexercised · Unexercised · Options
Name and Principal · Options (#) · Options (#) · Exercise · Option
PositionGrant DateExercisableUnexercisablePrice ($)Expiry Date
Lawrence Diamond, Former CEOJuly 21, 2021-30,000(a)$12.50July 21, 2031
Thomas Brodmerkel, Former CFOFebruary 27, 202011,667-$1.50February 27, 2030
December 28, 20202,000-$1.50December 28, 2020
Jenny Lindstrom, Former Chief Legal OfficerApril 12, 202115,0005,000(a)$15.50March 17, 2031
July 21, 2021-15,000(a)$12.50July 21, 2031
Michael Howe, Former Chief Executive Officer, The Good Clinic LLCJune 1, 20214,00016,000(a)$13.00June 17, 2031
July 21, 2021-10,000(a)$12.50July 21, 2031

The following table sets forth, for the year ended December 31, 2023, information relating to the compensation of each director who served on our Board of Directors during the fiscal year and who was not a named executive officer. This compensation was for their role as Director of the Company within the fiscal year.

Fees · Non-Equity · Nonqualified
Earned or · Incentive · Deferred · All
Paid in · Stock · Options · Plan · Compensation · Other
Name and PrincipalCash ($)AwardsAwardsCompensationEarningsCompensationTotal
Position($)($)($)(a)($)($)($)(g)($)
Thomas Brodmerkel (b)15,000---29,25044,250
Dr. H. Faraz Naqvi (c)7,500-----7,500
Juan Carlos Iturregui (e)30,000---84,073114,073
Sheila Schweitzer (d)15,000----15,00015,000
Allen Plunk15,000-----15,000
Mack Leath (f)-------
Jordan Balencic (f)-------
John Mitch (f)-------
(a)Amount represents the fair value of stock options granted during the period.
(b)Mr. Brodmerkel’s term as Chairman concluded on June 6, 2023.
(c)Effective April 14, 2023, Dr. H. Faraz Naqvi resigned as a director of the Company.
(d)On June 6, 2023, Sheila Schweitzer assumed the position as Chairperson of the Board. Sheila Schweitzer resigned as a director on December 15, 2023
(e)On December 15, 2023, Juan Carlos Iturregui resigned as a director of the Company.
(f)On December 15, 2023, Mack Leath, Jordan Balencic and John Mitch were elected to the Board of Directors
(g)Amount represents equity incentive benefits related to conversion of accrued compensation and outstanding notes payable

The table below shows the aggregate number of option awards outstanding at fiscal year-end for each of our current and former non-employee directors.

Number of
Outstanding Options
Name and PrincipalAs of
PositionDecember 31, 2023
Thomas Brodmerkel22,667
Dr. H. Faraz Naqvi4,000
Juan Carlos Iturregui3,700
Sheila Schweitzer20,700
Mack Leath-
Jordan Balencic-
John Mitch-
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.